Publications by authors named "C Kleinschnitz"
The inhibition of the neonatal Fc receptor (FcRn) is a promising therapeutic pathway in certain autoimmune disorders to reduce the amount of circulating pathogenic IgG autoantibodies by interfering with their recycling system. FcRn antibodies are currently being tested in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). This study aimed to investigate the therapeutic potential of an antibody targeting FcRn in the intracellular adhesion molecule 1 (ICAM1)-deficient NOD mouse-a model representative for many aspects of human CIDP.
View Article and Find Full Text PDFBackground: VR (Virtual Reality) has emerged as a recent treatment approach in neurorehabilitation. The feasibility of VR-guided therapy in the acute phase after stroke has not been assessed.
Methods: This was a cohort study of consecutive patients with suspected stroke who were admitted to the Essen University Hospital Stroke Unit between March 2022 and May 2022.
Article Synopsis
- B-cell-depletion with CD20 antibodies, specifically ocrelizumab (OCR) and ofatumumab (OFA), is an effective treatment for relapsing multiple sclerosis (RMS), but their comparative effectiveness in real-world settings was previously unknown.
- A cohort study involving 1,138 RMS patients was conducted in Germany, using propensity-score matching to compare the outcomes of OCR and OFA treatment, focusing on clinical relapses, MRI lesion changes, and disability progression.
- Results showed that OFA was non-inferior to OCR in overall effectiveness, but differences were noted in patients switching from other therapies, highlighting the need for more research on these specific cases.
Article Synopsis
- Diagnosing multiple sclerosis (MS) is complicated by varied symptoms and lack of specific biomarkers, compounded by the presence of concurrent autoimmune diseases (AID) and non-specific antibodies, which can hinder effective management.* -
- A study conducted on 315 patients from 2010 to 2017 revealed that 13.7% had concurrent AID, with autoimmune thyroiditis being the most common, but these conditions did not significantly affect MS progression or relapse rates over a median follow-up of 9 months.* -
- The findings suggest that while AIDs are prevalent at the onset of MS, they do not influence neurofilament light (NfL) levels, indicative of similar disease activity, pointing to a need
Article Synopsis
- Intragastric botulinum neurotoxin injections (IBNI) are being used as a weight-loss treatment, but an outbreak of severe iatrogenic botulism occurred in early 2023 in Europe after patients received this treatment in Turkey.
- A retrospective analysis was conducted on ten patients in Austria and Germany who experienced severe symptoms like double vision, swallowing difficulties, and paralysis after IBNI.
- Despite the severity of their conditions, all patients were hospitalized, many in intensive care, and ultimately recovered without lasting health issues, underscoring the need for awareness and risk mitigation in medical procedures involving botulinum neurotoxins.